Optimizing Care in IBD: Evidence, Cost, and Patient Goals
Tune into this CME Outfitters On Demand activity as expert faculty will highlight the clinical progression of IBD and its impact on patient outcomes and treatment choices. The panel will address risk/benefit of treatment options, direct and indirect cost, and clinical considerations critical to informed decisions about treatment plans for individuals with IBD.
This activity offers CE credit for:
- Physicians (CME)
- Nurses (CNE)
- Pharmacists (ACPE)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date: Friday, September 8, 2017
|Russell D. Cohen, MD, FACG, AGAF
Professor of Medicine, Pritzker School of Medicine
Director, Inflammatory Bowel Disease Center
Co-Director, Advanced IBD Fellowship Program
University of Chicago Medicine
|Huda-Marie Kandah, PharmD, BCPS
Clinical Coordinator, Specialty Pharmacy
University of Chicago Medicine
|Thomas A. Ullman, MD
Chief Medical Officer
Mount Sinai Doctors Faculty Practice
Senior Associate Dean for Clinical Affairs
Icahn School of Medicine at Mount Sinai
New York, NY
Inflammatory bowel diseases (IBD)–Crohn’s disease (CD), and ulcerative colitis (UC) –have low remission rates, indicating that conventional treatment approaches are suboptimal for patients. Treatment goals in IBD have evolving beyond symptomatic relief to sustained remission and mucosal healing to prevent continued damage, disability, and surgical intervention.
It is critical to identify patients at high risk for colectomy and plan their treatment appropriately with earlier, more aggressive utilization of immunomodulators and biologic agents; a step-down approach, in order to optimize mucosal healing and remission before permanent structural damage has occurred. Rising costs of specialty drugs are on the mind of specialty and managed care pharmacy directors, patients, and practicing physicians. When reviewing annual cost of care associated with IBD treatment, it is important to evaluate both direct costs (e.g. medication, surgery, hospitalization, lab tests) and indirect costs (e.g. quality of life, work/school productivity, absenteeism, disability).
In this CME Outfitters Live and On Demand, expert faculty will highlight the clinical progression of IBD and its impact on patient outcomes and treatment choices. The panel will address risk/benefit of treatment options, direct and indirect cost, and clinical considerations critical to informed decisions about treatment plans for individuals with IBD.
At the end of this CE activity, participants should be able to:
- Recognize the medical and financial cost of inadequately treated IBD.
- Evaluate a step-down versus step-up treatment approach in appropriate patients with IBD to achieve remission and decrease health care utilization.
The following learning objectives pertain only to those requesting CNE credit:
- Identify the medical and financial cost if inadequately treated IBD.
- Describe a step-down versus step-up treatment approach in appropriate patients with IBD to achieve remission and decrease health care utilization.
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs)
Universal Activity Number: 0376-0000-16-020-L01-P (live programs)
0376-0000-16-020-H01-P (recorded programs)
Activity Type: knowledge-based
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Russell D. Cohen, MD, FACG, AGAF has disclosed he serves as consultant to AbbVie, Inc.; Celgene Corporation; Entera Health, Inc.; Hospira, Inc.; Janssen Research & Development, LLC (Johnson & Johnson / Centocor); Pfizer Inc.; Sandoz Biopharmaceuticals; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc. He is the principal investigator in clinical trials for AstraZeneca; Celgene Corporation; Gilead Sciences, Inc.; Medimmune; Mesoblast Ltd.; Osiris Therapeutics, Inc.; Pfizer Inc.; Receptos, Inc.; RedHill Biopharma; Sanofi-aventis; and UCB, Inc. He serves on speakers bureau for AbbVie Inc. and Takeda Pharmaceuticals U.S.A., Inc.
Huda-Marie Kandah, PharmD, BCPS has no disclosures to report.
Dr. Thomas Ullman has disclosed he serves as consultant to American Regent, Inc. and Janssen Pharmaceuticals, Inc.
Jeffrey Helfand, DO, MS (peer reviewer) has no disclosures to report.
Kimberley Murray, RN, MS (peer reviewer) has no disclosures to report.
Jan Perez, CHCP (Planning Committee) has no disclosures to report.
Sharon Tordoff, CHCP (planning committee) has no disclosures to report.
Disclosures have been obtained from CME Outfitters staff: No disclosures to report.
Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
CME Outfitters, LLC, the faculty and Takeda Pharmaceuticals U.S.A., Inc. do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.